Maxim analyst Naz Rahman downgraded Assertio (ASRT) to Hold from Buy after the company announced it will be acquired by Garda Therapeutics for $18 per share, or $125.1M in total, plus a non-tradeable CVR tied to Sprix milestones.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT: